FatPipe and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
FATN:https://www.redchip.com/assets/access/fatn_accessFMST: https://www.redchip.com/assets/access/fmst_access
In an exclusive interview, Dr. Ragula Bhaskar, CEO of FatPipe, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is transforming enterprise connectivity through its patented, software-defined networking technologies. With a product suite spanning SD-WAN, Secure Access Service Edge (SASE), and Network Monitoring Services (NMS), FatPipe enables over 2,500 customers-including government agencies, financial institutions, and healthcare providers-to unify, secure, and optimize their networks across cloud, hybrid, and on-premise environments. Dr. Bhaskar highlights FatPipe's robust financial performance, including $17.9 million in revenue and $4.4 million in net income for fiscal 2024, and outlines the company's growth strategy focused on global expansion, product innovation, and deepening its high-margin, subscription-based revenue model. Positioned at the intersection of three multi-billion-dollar markets and operating as a "Rule of 40" business, FatPipe offers investors a compelling blend of profitability, scalability, and exposure to the accelerating digital infrastructure megatrend.
Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share the company's strategic vision for advancing uranium exploration in the world-renowned Athabasca Basin. Barnard details Foremost's expansive portfolio of 10 uranium properties spanning over 330,000 acres, including high-priority drill targets at Hatchet Lake and Murphy Lake South, where recent assays confirm strong mineralization and discovery potential. He also discusses the company's transformational partnership with Denison Mines, which brings technical, financial, and strategic backing from a C$2.9 billion uranium leader with a 19.13% equity stake in Foremost. With nuclear energy gaining momentum as a critical clean power source-and global pledges to triple capacity by 2050-Foremost is uniquely positioned to benefit from structural supply deficits and surging demand. Barnard highlights the company's fully funded 2025 exploration program, robust institutional backing, and dual exposure to uranium and lithium as key drivers of long-term shareholder value.
FATN and FMST are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About FatPipe, Inc.
FatPipe pioneered the concept of software-defined wide area networking (SD-WAN) and hybrid WANs that eliminate the need for hardware and software or cooperation from ISPs and allows companies and service providers to control multi-link network traffic. FatPipe currently has 12 U.S. patents related to multipath, software-defined networking. FatPipe products are sold by 200+ resellers worldwide. For more information, visit www.fatpipeinc.com. Follow us on X @FatPipe_Inc.
To learn more, visit www.fatpipeinc.com or contact sales321@fatpipeinc.com.
About Foremost
Foremost Clean Energy Ltd. (NASDAQ:FMST)(CSE:FAT)(WKN:A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.
Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec. For further information, please visit the Company's website at www.foremostcleanenergy.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave GentryRedChip Companies Inc.1-407-644-4256info@redchip.com
--END--
SOURCE: RedChip Companies, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
US stock futures steady as investors await payrolls data
(Reuters) -U.S. stock index futures held steady on Thursday as investors awaited the monthly jobs report for insights on the health of the labor market and the Federal Reserve's plans for monetary easing. The S&P 500 and Nasdaq closed at record highs after Wednesday's choppy session, boosted by gains in technology stocks and a trade agreement between the United States and Vietnam that eased concerns about prolonged trade tensions. The blue-chip Dow closed 1.3% below all-time highs touched in December. All eyes are on the nonfarm payrolls report for June, which is scheduled to be released at 8:30 a.m. ET (1230 GMT) - a day ahead of schedule because the U.S. markets are closed on July 4 for Independence Day. Trading volumes are expected to be light, with markets closing early, at 1 p.m. ET on Thursday. The data is expected to show the U.S. labor market slowed further in June, with the unemployment rate expected to have edged up to more than a three-and-a-half-year high of 4.3%, as economic uncertainty stemming from the Trump administration's policies curbed hiring. "Chair (Jerome) Powell, leading the camp for the Fed to keep rates on hold, argues that sticky inflation and a solid labor market mean that the policy rate should be kept mildly restrictive," ING analysts said in a note. "Clearly, any downside surprise in the jobs report would weaken his (Powell's) position and allow the market to push on with pricing a rate cut at the July meeting." Traders are attaching a 25% chance of the U.S. Federal Reserve cutting rates at the July meeting, according to CME Group's Fedwatch tool, up from about 20% a week ago. U.S. stocks dipped briefly on Wednesday after data showed private payrolls fell in June for the first time in more than two years. Other economic data on Thursday includes weekly jobless claims and the S&P Global and ISM services sector activity readings for June. Meanwhile, Republicans in the U.S. House of Representatives advanced President Donald Trump's massive tax-cut and spending bill toward a final yes-or-no vote, appearing to overcome internal party divisions over its cost. The legislation is expected to add $3.4 trillion to the nation's $36.2 trillion in debt over the next decade, according to nonpartisan analysts. By 5:49 a.m. ET (0949 GMT), S&P 500 e-minis were up 4 points, or 0.06%, Nasdaq 100 e-minis climbed 24.25 points, or 0.11%, and Dow e-minis added 30 points, or 0.07%. Shares of chip design software firms Synopsys and Cadence Design Systems climbed 6.7% and 5.9%, respectively, in premarket trading after the U.S. lifted export restrictions on chip design software to China, signaling a thaw in trade tensions between the world's top two economies. Tripadvisor climbed 4.9% after the Wall Street Journal reported activist investor Starboard Value had built a more than 9% stake in the online travel firm. Datadog jumped 10.2% after the cloud security firm was set to replace Juniper Networks on the S&P 500.
Yahoo
18 minutes ago
- Yahoo
Why Amgen Stock Popped by 4% Today
Investors continued to snap up shares following Monday's good news from the company. Analysts were generally positive about the latest development, too. 10 stocks we like better than Amgen › Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development. With that share price rise, Amgen easily beat the S&P 500 index, which slid by 0.1%. That news concerned Amgen's investigational stomach cancer drug, bemarituzumab. The company announced Monday that, in combination with chemotherapy, the treatment met its primary endpoint of of overall survival for the patients tested in a phase 3 clinical trial. It compared favorably to the results of patients only taking a placebo and receiving chemotherapy. The study had an enrollment of 547 patients who suffered from certain types of unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer. Amgen pointed out in its press release on the trial's results that gastric cancer is the fifth-leading cause of cancer-related death in the world, with over 650,000 fatalities. The two immediate analyst reactions to the news were both positive and complimentary. Piper Sandler's David Amsellem reiterated his overweight (i.e., buy) recommendation and $328 per share price target. According to reports, Amsellem said that while there were some concerns with the study, its results were positive, and Amgen could have quite a successful drug on its hands. As cancer is a persistent and tough challenge, any advancement in its treatment is cause for optimism. While Amgen could have provided more details of the study (it pledged to do so in an unspecified presentation in the near future), the rough outlines of bemarituzumab are encouraging. The company might very well be on the cusp of success with the drug. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool has a disclosure policy. Why Amgen Stock Popped by 4% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Global Growth Companies With High Insider Ownership In July 2025
In the wake of record highs for the S&P 500 and Nasdaq Composite, driven by easing geopolitical tensions and promising trade developments, global markets are reflecting a cautiously optimistic sentiment despite inflationary pressures. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those who know the business best, aligning well with current market conditions that favor stability and strategic foresight. Name Insider Ownership Earnings Growth Zhejiang Leapmotor Technology (SEHK:9863) 15.6% 60.5% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 23.5% Samyang Foods (KOSE:A003230) 11.7% 24.8% Pharma Mar (BME:PHM) 11.8% 44.9% Marinomed Biotech (WBAG:MARI) 29.7% 20.2% Laopu Gold (SEHK:6181) 35.5% 41.2% KebNi (OM:KEBNI B) 38.3% 94.5% Fulin Precision (SZSE:300432) 13.6% 43.7% Elliptic Laboratories (OB:ELABS) 24.4% 79% Bergen Carbon Solutions (OB:BCS) 12% 63.2% Click here to see the full list of 835 stocks from our Fast Growing Global Companies With High Insider Ownership screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: BrightGene Bio-Medical Technology Co., Ltd. is a pharmaceutical company involved in the research, development, manufacture, and commercialization of pharmaceutical products in China with a market cap of CN¥22.34 billion. Operations: BrightGene Bio-Medical Technology Co., Ltd. generates revenue through its pharmaceutical product research, development, manufacturing, and commercialization activities in China. Insider Ownership: 26.9% Earnings Growth Forecast: 32.1% p.a. BrightGene Bio-Medical Technology is experiencing significant earnings growth, forecasted at 32.1% annually, outpacing the Chinese market. Despite high volatility in its share price and challenges in covering interest payments with earnings, it remains financially promising due to robust revenue growth projections of 17.4%. Recent advancements include promising Phase 2 results for its dual agonist BGM0504 and novel amylin analog BGM1812, highlighting potential in weight management and metabolic disease treatment. Get an in-depth perspective on BrightGene Bio-Medical Technology's performance by reading our analyst estimates report here. According our valuation report, there's an indication that BrightGene Bio-Medical Technology's share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★☆ Overview: Xi'an Bright Laser Technologies Co., Ltd. provides metal additive manufacturing and repairing solutions in China, with a market cap of CN¥15.22 billion. Operations: Xi'an Bright Laser Technologies Co., Ltd. generates revenue through its metal additive manufacturing and repairing solutions within the People's Republic of China. Insider Ownership: 24.8% Earnings Growth Forecast: 54.2% p.a. Xi'an Bright Laser Technologies is positioned for rapid growth, with revenue expected to increase 36.7% annually, surpassing the broader Chinese market. Despite a volatile share price and declining profit margins from 11.3% to 6.6%, earnings are projected to grow significantly at 54.2% per year, highlighting strong potential in the laser technology sector. Recent financials show first-quarter sales of CNY 227 million but a net loss of CNY 14.95 million compared to last year's profit, indicating challenges alongside growth prospects. Navigate through the intricacies of Xi'an Bright Laser TechnologiesLtd with our comprehensive analyst estimates report here. The valuation report we've compiled suggests that Xi'an Bright Laser TechnologiesLtd's current price could be inflated. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥12.12 billion. Operations: The company generates revenue through its activities in research, production, and marketing of Chinese medicinal products within China and on an international scale. Insider Ownership: 23.1% Earnings Growth Forecast: 18.9% p.a. Zhejiang Jolly Pharmaceutical showcases promising growth potential with revenue forecasted to rise over 20% annually, outpacing the Chinese market. Recent earnings reveal a net income increase to CNY 181.15 million, reflecting robust performance despite dividends not being fully covered by free cash flows. Trading at a significant discount to its estimated fair value and expected high return on equity further enhance its investment appeal, though insider trading activity remains minimal in recent months. Click here and access our complete growth analysis report to understand the dynamics of Zhejiang Jolly PharmaceuticalLTD. The valuation report we've compiled suggests that Zhejiang Jolly PharmaceuticalLTD's current price could be quite moderate. Click through to start exploring the rest of the 832 Fast Growing Global Companies With High Insider Ownership now. Want To Explore Some Alternatives? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SHSE:688166 SHSE:688333 and SZSE:300181. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
